The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease
Open accessAbstract
BACKGROUND: Safe and effective delivery of therapeutic drugs to the brain is important for successful therapy of Alzheimer's disease (AD). PURPOSE: To develop Huperzine A (HupA)-loaded, mucoadhesive and targeted polylactide-co-glycoside (PLGA) nanoparticles (NPs) with surface modification by lactoferrin (Lf)-conjugated N-trimethylated chitosan (TMC) (HupA Lf-TMC NPs) for efficient intranasal delivery of HupA to the brain for AD treatment. METHODS: HupA Lf-TMC NPs were prepared using the emulsion-solvent evaporation method and optimized using the Box-Behnken design. The particle size, zeta potential, drug entrapment efficiency, adhesion and in vitro release behavior were investigated. The cellular uptake was investigated by fluorescence microscopy and flow cytometry. MTT assay was used to evaluate the cytotoxicity of the NPs. In vivo imaging system was used to investigate brain targeting effect of NPs after intranasal administration. The biodistribution of Hup-A NPs after intranasal administration was determined by liquid chromatography-tandem mass spectrometry. RESULTS: Optimized HupA Lf-TMC NPs had a particle size of 153.2±13.7 nm, polydispersity index of 0.229±0.078, zeta potential of +35.6±5.2 mV, drug entrapment efficiency of 73.8%±5.7%, and sustained release in vitro over a 48 h period. Adsorption of mucin onto Lf-TMC NPs was 86.9%±1.8%, which was significantly higher than that onto PLGA NPs (32.1%±2.5%). HupA Lf-TMC NPs showed lower toxicity in the 16HBE cell line compared with HupA solution. Qualitative and quantitative cellular uptake experiments indicated that accumulation of Lf-TMC NPs was higher than nontargeted analogs in 16HBE and SH-SY5Y cells. In vivo imaging results showed that Lf-TMC NPs exhibited a higher fluorescence intensity in the brain and a longer residence time than nontargeted NPs. After intranasal administration, Lf-TMC NPs facilitated the distribution of HupA in the brain, and the values of the drug targeting index in the mouse olfactory bulb, cerebrum (with hippocampus removal), cerebellum, and hippocampus were about 2.0, 1.6, 1.9, and 1.9, respectively. CONCLUSION: Lf-TMC NPs have good sustained-release effect, adhesion and targeting ability, and have a broad application prospect as a nasal drug delivery carrier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Regional dissociations within the hippocampus-memory and anxiety
Bannerman, D. M., Rawlins, J. N. P., McHugh, S. B., Deacon, R. M. J., Yee, B. K., Bast, T., Zhang, W.-N., Pothuizen, H. H. J., & Feldon, J. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.03.004 · Cited by 1,462
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Nanoparticles for direct nose-to-brain delivery of drugs
Mistry, A., Stolnik, S., & Illum, L. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.019 · Cited by 734
Brain drug delivery of small molecules using immunoliposomes
Huwyler, J., Wu, D., & Pardridge, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14164 · Cited by 656
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review
Djupesland, P. G. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0108-9 · Cited by 563
Studies on the Internalization Mechanism of Cationic Cell-penetrating Peptides
Drin, G., Cottin, S., Blanc, E., Rees, A. R., & Temsamani, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303938200 · Cited by 530
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Chitosan in nasal delivery systems for therapeutic drugs
Casettari, L., & Illum, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.003 · Cited by 444
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Self-citationAgrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Elmowafy, E. M., Tiboni, M., & Soliman, M. E. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00439-x · Cited by 621
Chitosan and chitosan coating nanoparticles for the treatment of brain disease
Yu, S., Xu, X., Feng, J., Liu, M., & Hu, K. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.012 · Cited by 340
On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles
Formica, M. L., Real, D. A., Picchio, M. L., Catlin, E., Donnelly, R. F., & Paredes, A. J. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101631 · Cited by 282
Metadata
- Authors
- Meng, Q., Wang, A., Hua, H., Jiang, Y., Wang, Y., Mu, H., Wu, Z., & Sun, K.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-02
- Volume
- Volume 13
- Pages
- 705-718
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2792702566
- Cited by
- 310
- References
- 47
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.2147/ijn.s151474
- The paper
- Meng, Q., Wang, A., Hua, H., Jiang, Y., Wang, Y., Mu, H., Wu, Z., & Sun, K. (2018). Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s151474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.